Press release – Daiichi Sankyo and LYSA-LYSARC-CALYM
Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with Relapsed/Refractory B-Cell Lymphoma
- Phase 2 trial to evaluate valemetostat in patients with five disease subtypes along with a planned robust translational research program
Tokyo, Basking Ridge, N.J., Munich and Lyon – (February 24, 2021) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and LYSA-LYSARC-CALYM today announced that they have entered a strategic research collaboration to study valemetostat (DS-3201), Daiichi Sankyo’s potential first-in-class EZH1/2 dual inhibitor, in B-cell malignancies starting with a phase 2 study in patients with five subtypes of relapsed/refractory B-cell lymphoma.
The collaboration brings together Daiichi Sankyo’s innovative science and the multidisciplinary expertise of the Lymphoma Study Association (LYSA), the Lymphoma Academic Research Organization (LYSARC) and the CALYM research consortium to conduct clinical and translational research that will build upon the ongoing phase 1 study of valemetostat in patients with relapsed/refractory non-Hodgkin lymphoma.
To know more, download the press release